A Phase 3, Multi-center, Open-label, Single-arm Clinical Trial to Assess the Long-term Safety and Tolerability of Topical CyclASol for the Treatment of Dry Eye Disease in Subjects Who Completed the Clinical Trial CYS-004
Latest Information Update: 18 Oct 2023
At a glance
- Drugs Ciclosporin (Primary)
- Indications Dry eyes
- Focus Adverse reactions
- Sponsors Novaliq
- 05 Jul 2022 Status changed from active, no longer recruiting to completed.
- 28 Apr 2021 According to a Novaliq media release, the trial has been completely enrolled with a total of 200 participants.
- 28 Apr 2021 Status changed from recruiting to active, no longer recruiting, according to a Novaliq media release.